A better understanding of these mechanisms is crucial for developing innovative strategies aimed at optimizing the use of CDK4/6 inhibitors, even in tumours with Rb deficiency or mutation, which are usually resistant to these agents [19]. This evidence concerns the gene CDK4 and neoplasm.